A leader in immune-

modulating cell therapies

for patients with unmet

needs in autoimmune

diseases and cancer

According to the U.S. Department of Health and Human Services, approximately 23 million Americans are affected by more than 100 autoimmune conditions, most of which have no cure.

iCell is a pioneer in the clinical development of CAR-engineered cell therapies for B cell-mediated autoimmune diseases including:

  • Systemic Lupus Erythematosus / Lupus Nephritis

  • Other Autoimmune Conditions (more than 25 potential indications)

    We are also leading the charge to develop novel cell therapies to treat cancers including:

  • T-cell Malignancies

  • Acute Myeloid Leukemia

Since 2014, our experienced clinical research, product development and manufacturing teams have been developing first-in-class chimeric antigen receptor (CAR) cell therapies to be cost effective treatments for autoimmune diseases including lupus as well as cancer:

Our innovative cell-therapy platform
technologies include:

  • Compound Cars (cCARs)

  • Non-Gene Editing CAR Technology for T-Cell Malignancies

  • Universal CARs including Super NK-Cells